⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28183997 | 0.71 | ALDH1A1 (0.43) | — | |
| SCHEMBL11334103 | 0.69 | — | — | |
| SCHEMBL15149 | 0.69 | — | — | |
| SCHEMBL16694847 | 0.69 | — | — | |
| SCHEMBL28151691 | 0.67 | LPO (0.44) | — | |
| SCHEMBL21034097 | 0.67 | — | — | |
| SCHEMBL28036586 | 0.67 | ALDH1A1 (0.36) | — | |
| SCHEMBL28862737 | 0.67 | — | — | |
| SCHEMBL14032737 | 0.67 | — | — | |
| SCHEMBL1942801 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105358151-B | For treating the compound of Duchenne-Arandisease | 豪夫迈·罗氏有限公司 | 2019-04-12 | — | — | CN | claimed |
| CN-104349777-B | Compounds for the treatment of spinal muscular atrophy | PTC医疗公司 | 2018-05-01 | — | — | CN | claimed |
| CN-105814055-B | As the condensed imidazole and pyrazole derivatives of TNF active regulators | UCB生物制药私人有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-105358151-B | For treating the compound of Duchenne-Arandisease | 豪夫迈·罗氏有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-108602802-A | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-105814054-B | Condensed imidazole and pyrazole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-25 | — | — | CN | disclosed |
| CN-108299314-A | Compound for treating Duchenne-Arandisease | PTC医疗公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-108264512-A | Nitrogenous fused heterocyclic compound, preparation method, intermediate, composition and application | 上海医药集团股份有限公司 | 2018-07-10 | — | — | CN | disclosed |
| CN-104244944-B | For treating the compound of spinal muscular atrophy | PTC医疗公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-108055865-A | For the new TNF α structure for the treatment of | UCB生物制药私人有限公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-108026045-A | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | 奥瑞基尼探索技术有限公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-104981470-B | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | 拜耳制药股份公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106414440-A | Aryl and heteroaryl substituted imidazo [1,2-a ] pyridine-3-carboxamides and their use | 拜耳制药股份公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-104619709-B | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-105814055-A | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814054-A | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105358151-A | Compounds for treating spinal muscular atrophy | HOFFMANN LA ROCHE | 2016-02-24 | — | — | CN | disclosed |
| CN-104244944-A | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS INC | 2014-12-24 | — | — | CN | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |